Commentary II

We rant

The biotech industry may sound sexy to the public when the general media picks up on the latest in angiogenesis inhibitors for cancer, but that kind of excitement is soon forgotten when the issue turns to safety. And just as the media is likely to over-hype the benefits of some new scientific discovery, it is equally likely to over-hype and misconstrue safety issues when they arise.

The New York Times' reporting of Wyeth-Ayerst's pain product Duract clearly illustrates the kinds of misinformation that the public can get from media coverage that is either ignorant, biased or just plain wrong.